{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:40:33Z","timestamp":1784806833212,"version":"3.55.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Ischemic and non-ischemic cardiac diseases including arrhythmogenic cardiomyopathy and myocardial infarction, remain one of the leading causes of death worldwide despite significant advances in cardiovascular therapeutics. Current treatment strategies such as \u03b2-blockers, angiotensin-converting-enzyme inhibitors, and cardiac surgical interventions that include implantations of pacemakers and cardioverter-defibrillators are effective but often associated with serious side effects. In recent years, multiple cell-based therapies have emerged, aiming either to regeneration of myocardial or myofascial tissues or to correct defective gene using gene-transfer tools. Adeno-associated virus (AAVs), initially identified as contaminants of adeno-virus preparations, have since become one of the most important viral vectors for gene-transfer, especially in mammalian cells. This review analyzes and summarizes various AAV serotypes utilized in gene therapy programs for preclinical and clinical assays for cardiac disease.<\/jats:p>","DOI":"10.3389\/fmed.2025.1678325","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:20:14Z","timestamp":1760620814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["AAV viral vectors as therapeutic interventions for inherited or non-inherited cardiac disorders: current aspects and future prospects"],"prefix":"10.3389","volume":"12","author":[{"given":"Vivek","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalimuthu","family":"Kalishwaralal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Pratap","family":"Barnwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/jcm12041412","article-title":"Long-term outcomes of tachycardia-induced cardiomyopathy compared with idiopathic dilated cardiomyopathy","volume":"12","author":"Katz","year":"2023","journal-title":"J Clin Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cjca.2022.01.016","article-title":"Ventricular tachycardia burden and mortality: association or causality?","volume":"38","author":"Samuel","year":"2022","journal-title":"Can J Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e70109","DOI":"10.1002\/clc.70109","article-title":"Unmasking arrhythmia mortality: a 25-year analysis of trends and disparities in the United States (1999\u20132023)","volume":"48","author":"Azeem","year":"2025","journal-title":"Clin Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","article-title":"Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions","volume":"113","author":"Sanganalmath","year":"2013","journal-title":"Circ Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/trf.12826","article-title":"Cell-based therapies for cardiac disease: a cellular therapist's perspective","volume":"55","author":"Young","year":"2014","journal-title":"Transfusion"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.celbio.2025.100075","article-title":"Geometrically controlled cardiac microtissues promote vascularization and reduce inflammation in vitro and in vivo","author":"Zhao","year":"2025","journal-title":"Cell Biomater."},{"key":"B7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00109-022-02208-0","article-title":"Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective","volume":"100","author":"Schwartze","year":"2022","journal-title":"J Mol Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10741-017-9622-7","article-title":"Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases","volume":"22","author":"Bera","year":"2017","journal-title":"Heart Fail Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1128\/JVI.00161-16","article-title":"Characterization of the adeno-associated virus 1 and 6 sialic acid binding site","volume":"90","author":"Huang","year":"2016","journal-title":"J Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"9093","DOI":"10.1128\/JVI.00895-06","article-title":"Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6","volume":"80","author":"Wu","year":"2006","journal-title":"J Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/mt.2013.226","article-title":"Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy","volume":"21","author":"Flotte","year":"2013","journal-title":"Mol Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrd3572","article-title":"Gene therapies advance towards finish line","volume":"10","author":"Mullard","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1586\/17512433.2014.852065","article-title":"Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera\u00ae)","volume":"7","author":"Salmon","year":"2014","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1128\/jvi.45.2.555-564.1983","article-title":"Nucleotide sequence and organization of the adeno-associated virus 2 genome","volume":"45","author":"Srivastava","year":"1983","journal-title":"J Virol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-77-6-1111","article-title":"Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection","volume":"77","author":"Ponnazhagan","year":"1996","journal-title":"J Gen Virol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1089\/104303402760128612","article-title":"Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain","volume":"13","author":"Janson","year":"","journal-title":"Hum Gene Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1089\/hum.2020.099","article-title":"Development of a clinical candidate AAV3 vector for gene therapy of Hemophilia B","volume":"31","author":"Brown","year":"2020","journal-title":"Hum Gene Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.1128\/JVI.75.15.6884-6893.2001","article-title":"Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity","volume":"75","author":"Kaludov","year":"2001","journal-title":"J Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1128\/JVI.79.8.5047-5058.2005","article-title":"Structure of adeno-associated virus Type 4","volume":"79","author":"Padron","year":"2005","journal-title":"J Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/sj.gt.3302554","article-title":"Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS","volume":"12","author":"Liu","year":"2005","journal-title":"Gene Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/eurheartj\/ehr447","article-title":"AAV6.\u03b2ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model.","volume":"34","author":"Raake","year":"2013","journal-title":"Eur Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41434-021-00230-4","article-title":"Liver targeting with rAAV7: balancing tropism with immune profiles","volume":"28","author":"Flotte","year":"2021","journal-title":"Gene Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e01163","DOI":"10.1128\/jvi.01163-23","article-title":"Characterization and biodistribution of under-employed gene therapy vector AAV7","volume":"97","author":"Yost","year":"2023","journal-title":"J Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.omtm.2024.101193","article-title":"AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich's ataxia","volume":"32","author":"Chang","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.gendis.2023.02.010","article-title":"Recombinant adeno-associated virus 8 vector in gene therapy: opportunities and challenges","volume":"11","author":"Zhao","year":"2023","journal-title":"Genes Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of Intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.omtm.2024.101263","article-title":"Prenatal AAV9-GFP administration in fetal lambs results in transduction of female germ cells and maternal exposure to virus","volume":"32","author":"Borges","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.omtm.2023.05.017","article-title":"Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy","volume":"30","author":"Le Guiner","year":"2023","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.hrthm.2024.02.001","article-title":"Adeno-associated virus-mediated gene therapy for cardiac tachyarrhythmia: a systematic review and meta-analysis","volume":"21","author":"Mundisugih","year":"2024","journal-title":"Heart Rhythm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/biomedicines12061351","article-title":"Exploring the therapeutic potential of gene therapy in arrhythmogenic right ventricular cardiomyopathy","volume":"12","author":"Mundisugih","year":"2024","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E004305","DOI":"10.1161\/CIRCGEN.123.004305","article-title":"AAV-mediated delivery of plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans","volume":"17","author":"van Opbergen","year":"2024","journal-title":"Circ Genom Precis Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/CIRCRESAHA.119.315956","article-title":"AAV gene therapy prevents and reverses heart failure in a murine knockout model of barth syndrome","volume":"126","author":"Wang","year":"2020","journal-title":"Circ Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.medp.2025.100073","article-title":"Hypertrophic cardiomyopathy: current understanding and emerging therapeutics","volume":"2","author":"Dai","year":"2025","journal-title":"Med Plus."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-57481-7","article-title":"AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models","volume":"16","author":"Greer-Short","year":"2025","journal-title":"Nat Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"92ra64","DOI":"10.1126\/scitranslmed.3002097","article-title":"Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model","volume":"3","author":"Pleger","year":"2011","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"S792","DOI":"10.1161\/circ.118.suppl_18.S_792","article-title":"Abstract 2883: Retroinfusion-facilitated Inotropic AAV9-S100A1 Gene therapy restores global cardiac function in a clinically relevant pig heart failure model","volume":"118","author":"Pleger","year":"2008","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e166713","DOI":"10.1172\/jci.insight.166713","article-title":"Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-025-00787-w","article-title":"AAV9-cBIN1 gene therapy rescues chronic heart failure due to ischemic cardiomyopathy in a canine model","volume":"5","author":"Khan","year":"2025","journal-title":"Commun Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1161\/01.CIR.100.23.2308","article-title":"Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a","volume":"100","author":"del MonteF Harding","year":"1999","journal-title":"Circulation."},{"key":"B44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cardfail.2015.09.012","article-title":"CUPID 2: a Phase 2b trial investigating the efficacy and safety of the intracoronary administration of AAV1\/SERCA2a in patients with advanced heart failure","volume":"21","author":"Greenberg","year":"2015","journal-title":"J Card Fail."},{"key":"B46","doi-asserted-by":"publisher","first-page":"609","DOI":"10.18609\/cgti.2020.073","article-title":"Consideration of clinical translation of cardiac AAV gene therapy","volume":"6","author":"Yamada","year":"2020","journal-title":"Cell Gene Ther Insights."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-54635-x","article-title":"AAV delivery strategy with mechanical support for safe and efficacious cardiac gene transfer in swine","volume":"15","author":"Mazurek","year":"2024","journal-title":"Nat Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/hum.2023.057","article-title":"Progress in bioengineering of myotropic adeno-associated viral gene therapy vectors","volume":"34","author":"Liu","year":"2023","journal-title":"Hum Gene Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1743-422X-10-50","article-title":"Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution","volume":"10","author":"Yang","year":"2013","journal-title":"Virol J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1073\/pnas.0813207106","article-title":"A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection","volume":"106","author":"Yang","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13395-024-00341-7","article-title":"Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors","volume":"14","author":"Ji","year":"2024","journal-title":"Skelet Muscle."},{"key":"B53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.122.063759","article-title":"Extracellular vesicle-encapsulated adeno-associated viruses for therapeutic gene delivery to the heart","volume":"148","author":"Li","year":"2023","journal-title":"Circulation."},{"key":"B54","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41536-024-00380-0","article-title":"Cardiac bridging integrator 1 gene therapy rescues chronic non-ischemic heart failure in minipigs","volume":"9","author":"Li","year":"2024","journal-title":"NPJ Regen Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/molecules30040962","article-title":"Advanced nanomedicine delivery systems for cardiovascular diseases: viral and non-viral strategies in targeted therapy","volume":"30","author":"Chen","year":"2025","journal-title":"Molecules"},{"key":"B57","doi-asserted-by":"publisher","first-page":"146820","DOI":"10.1016\/j.gene.2022.146820","article-title":"Expression of the \u03b21-adrenergic receptor (ADRB1) gene in the myocardium and \u03b2-adrenergic reactivity of the body in patients with a history of myocardium infraction","volume":"844","author":"Muslimova","year":"2022","journal-title":"Gene."},{"key":"B58","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/164_2024_720","article-title":"Roles of \u03b2-adrenoceptor subtypes and therapeutics in human cardiovascular disease: heart failure, tachyarrhythmias and other cardiovascular disorders","volume":"285","author":"Wong","year":"2024","journal-title":"Handb Exp Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1134\/S000635091905021X","article-title":"Myocardial \u03b12-adrenoceptors as therapeutic targets to prevent cardiac hypertrophy and heart failure","volume":"64","author":"Pimenov","year":"2019","journal-title":"Biophysics."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.115.019860","article-title":"\u03b2-adrenergic receptors cooperate with transcription factors: the \u2018STAT' of their union.","volume":"133","author":"Balligand","year":"2016","journal-title":"Circulation."},{"key":"B61","doi-asserted-by":"publisher","first-page":"925692","DOI":"10.3389\/fcvm.2022.925692","volume":"9","author":"Mahmood","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jacbts.2024.10.008","article-title":"Therapeutic efficacy of a novel pharmacologic GRK2 inhibitor in multiple animal models of heart failure","volume":"10","author":"Roy","year":"2025","journal-title":"JACC Basic Transl Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yjmcc.2022.07.008","article-title":"GRK2 in cardiovascular disease and its potential as a therapeutic target","volume":"172","author":"Ferrero","year":"2022","journal-title":"J Mol Cell Cardiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"484837","DOI":"10.3389\/fcvm.2019.00150","article-title":"An update on the multifaceted roles of STAT3 in the Heart","volume":"6","author":"Harhous","year":"2019","journal-title":"Front Cardiovasc Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.115.017472","article-title":"Critical roles of STAT3 in \u03b2-adrenergic functions in the heart","volume":"133","author":"Zhang","year":"2015","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-021-00898-0","article-title":"Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function","volume":"116","author":"Comit\u00e0","year":"2021","journal-title":"Basic Res Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-023-01003-3","article-title":"Perspective: mitochondrial STAT3 in cardioprotection","volume":"118","author":"Kleinbongard","year":"2023","journal-title":"Basic Res Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-016-0543-8","article-title":"Understanding STAT3 signaling in cardiac ischemia","volume":"111","author":"O'Sullivan","year":"2016","journal-title":"Basic Res Cardiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1126\/science.2164258","article-title":"Mediation of cardioprotection by transforming growth factor-\u03b2","volume":"249","author":"Lefer","year":"1990","journal-title":"Science."},{"key":"B70","doi-asserted-by":"publisher","first-page":"478333","DOI":"10.3389\/fcvm.2019.00140","article-title":"The role of the TGF-\u03b2 superfamily in myocardial infarction","volume":"6","author":"Hanna","year":"2019","journal-title":"Front Cardiovasc Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","article-title":"Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling","volume":"51","author":"Dobaczewski","year":"2011","journal-title":"J Mol Cell Cardiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-021-00646-w","article-title":"Transforming growth factor-\u03b2 in myocardial disease","volume":"19","author":"Frangogiannis","year":"2022","journal-title":"Nat Rev Cardiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-04361-1","article-title":"ADAMTSL3 knock-out mice develop cardiac dysfunction and dilatation with increased TGF\u03b2 signalling after pressure overload","volume":"5","author":"Rypdal","year":"2022","journal-title":"Commun Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0092-8674(01)00242-2","article-title":"The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms","volume":"104","author":"Seidman","year":"2001","journal-title":"Cell."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","article-title":"Mechanisms and models in heart failure: the biomechanical model and beyond","volume":"111","author":"Mann","year":"2005","journal-title":"Circulation."},{"key":"B76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ehf2.12267","article-title":"Genetic determinants of heart failure: facts and numbers","volume":"5","author":"Czepluch","year":"2018","journal-title":"ESC Heart Fail."},{"key":"B77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1161\/01.RES.61.1.70","article-title":"Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure","volume":"61","author":"Gwathmey","year":"1987","journal-title":"Circ Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10741-013-9373-z","article-title":"Calcium handling proteins: structure, function, and modulation by exercise","volume":"19","author":"Locatelli","year":"2014","journal-title":"Heart Fail Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/joim.13308","article-title":"Gene therapy for ischaemic heart disease and heart failure","volume":"290","author":"Korpela","year":"2021","journal-title":"J Intern Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41569-018-0145-2","article-title":"Transient receptor potential channels in cardiac health and disease","volume":"16","author":"Hof","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"E4582","DOI":"10.1073\/pnas.1621384114","article-title":"Major contribution of the 3\/6\/7 class of TRPC channels to myocardial ischemia\/reperfusion and cellular hypoxia\/reoxygenation injuries","volume":"114","author":"He","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B82","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/cvr\/cvv205","article-title":"Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation","volume":"108","author":"Rincon","year":"2015","journal-title":"Cardiovasc Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1752-8062.2010.00190.x","article-title":"Comparative cardiac gene delivery of adeno-associated virus serotypes 1\u20139 reveals that AAV6 mediates the most efficient transduction in mouse heart","volume":"3","author":"Zincarelli","year":"2010","journal-title":"Clin Transl Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e019338","DOI":"10.1161\/JAHA.120.019338","article-title":"Complex relationship between cardiac fibroblasts and cardiomyocytes in health and disease","volume":"10","author":"Hall","year":"2021","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","article-title":"Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs."},{"key":"B88","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jchf.2013.09.008","article-title":"Design of a phase 2b trial of intracoronary administration of AAV1\/SERCA2a in patients with advanced heart failure The CUPID 2 trial (calcium Up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)","volume":"2","author":"Greenberg","year":"2014","journal-title":"JACC Heart Fail."},{"key":"B89","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/hum.2006.17.487","article-title":"Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation","volume":"17","author":"Ross","year":"2006","journal-title":"Hum Gene Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","article-title":"Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis","volume":"26","author":"Le Meur","year":"2018","journal-title":"Mol Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41434-019-0104-5","article-title":"Superior human hepatocyte transduction with adeno-associated virus vector serotype 7","volume":"26","author":"Shao","year":"2019","journal-title":"Gene Ther."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2025.04.006","article-title":"Efficient AAV8 delivery to the liver via isolated hepatic perfusion and analysis of hepatic lobule transduction patterns","author":"Wang","year":"2025","journal-title":"Liver Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-30800-3","article-title":"AAV serotype 8-mediated liver specific GNMT expression delays progression of hepatocellular carcinoma and prevents carbon tetrachloride-induced liver damage","volume":"8","author":"Fang","year":"2018","journal-title":"Sci Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cardfail.2024.10.138","article-title":"GenePHIT phase 2 study design: a double blind, placebo-controlled trial To assess efficacy, safety, and tolerability of Ab-1002 gene therapy in adults with heart failure","volume":"31","author":"Henry","year":"2025","journal-title":"J Card Fail"},{"key":"B98","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.cardfail.2014.06.036","article-title":"SDF-1 Plasmid Attenuates adverse remodeling in ischemic heart failure patients in a randomized phase II trial","volume":"20","author":"Chung","year":"2014","journal-title":"J Card Fail."},{"key":"B99","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."},{"key":"B100","unstructured":"Study Details. AB-1002 in Patients with Class III Heart Failure"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1678325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:20:16Z","timestamp":1760620816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1678325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":100,"alternative-id":["10.3389\/fmed.2025.1678325"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1678325","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"article-number":"1678325"}}